Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

2-mercaptoethanol (2-ME)-based IATs or polybrene method mitigates the interference of anti-CD38 immunotherapy on blood compatibility tests

Ye Zhou, Leiyu Chen, Tianshu Jiang, Liangfeng Fan, Hang Lei, Yuqing Wang, Hasiyati Heililahong, Jianqing Mi, Danxin Du, Tianhong Miao, Rong Xia, Xuefeng Wang, Dong Xiang, Xiaohong Cai, Xiaofeng Tang
doi: https://doi.org/10.1101/2020.12.14.20238311
Ye Zhou
1Department of Blood Transfusion, Changzheng Hospital, Naval Medical University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leiyu Chen
1Department of Blood Transfusion, Changzheng Hospital, Naval Medical University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tianshu Jiang
1Department of Blood Transfusion, Changzheng Hospital, Naval Medical University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liangfeng Fan
2Blood Group Reference Laboratory, Shanghai Blood Center, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hang Lei
3Department of Blood Transfusion, Laboratory Diagnosis Center, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuqing Wang
3Department of Blood Transfusion, Laboratory Diagnosis Center, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hasiyati Heililahong
3Department of Blood Transfusion, Laboratory Diagnosis Center, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianqing Mi
4Department of Hematology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danxin Du
5Department of Blood Transfusion, Huashan Hospital Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tianhong Miao
6Blood Group Reference Laboratory, Beijing Red Cross Blood Center, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rong Xia
5Department of Blood Transfusion, Huashan Hospital Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuefeng Wang
3Department of Blood Transfusion, Laboratory Diagnosis Center, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dong Xiang
2Blood Group Reference Laboratory, Shanghai Blood Center, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jack_tangxf@163.com cxh8407@126.com xiangdong@sbc.org.cn
Xiaohong Cai
3Department of Blood Transfusion, Laboratory Diagnosis Center, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jack_tangxf@163.com cxh8407@126.com xiangdong@sbc.org.cn
Xiaofeng Tang
1Department of Blood Transfusion, Changzheng Hospital, Naval Medical University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jack_tangxf@163.com cxh8407@126.com xiangdong@sbc.org.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Treating red blood cells (RBCs) with dithiothreitol (DTT) is a wildly-recommended to overcome the interference of anti-CD38 immunotherapy with blood compatibility testing. Nevertheless, DTT can be hard to obtain in clinical laboratory, while its use in routine practice may be time-consuming. In the following study, we explored the feasibility of using a commercial 2-mercaptoethanol (2-ME) working solution or the time-saving polybrene method to mitigate the daratumumab (DARA) interference.

Materials and Methods Antibody screening and cross-matching were performed using 2-ME or DTT-based indirect antiglobulin tests (IATs) and polybrene method (human IgG anti-E same IATs titer as DARA as positive control) on 37 samples, and these samples were from patients enrolled in the “Several methods resolve the interference of anti-CD38 monoclonal antibody on blood compatibility tests” clinical trial (www.chictr.org.cn identifier: ChiCTR2000040761). Most clinically important blood group antigens on RBCs were detected after treatment with 2-ME or DTT. Hemoglobin values were compared after 69 units RBCs were transfused with compatible cross-matching results by a 2-ME-based method or polybrene test.

Results Treating RBCs with 2-ME eliminates the DARA interference with the antibody screening or cross-matching; yet, K antigen is denatured during treatment. DARA with 2+ agglutinations of anti-E control does not interfere with antibody screening and cross-matching via polybrene method. After RBCs transfusion with a negative cross-matching test by 2-ME-based IATs or polybrene method, hemoglobin significantly increased without adverse transfusion reactions.

Conclusion 2-ME-based IATs or polybrene method could be used to mitigate DARA interference as DTT.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ChiCTR2000040761 (http://www.chictr.org.cn)

Funding Statement

This work was supported by WeiGao Science Foundation of Chinese Society of Blood Transfusion (CSBT-WG-2019-01), and National Natural Science Foundation of China (82000183).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by all 5 ethics committees of the participated institutions; they are the ethics committee of Changzheng Hospital, the ethics committee of Shanghai Blood Center, the ethics committee of Ruijin Hospital, the ethics committee of Huashan Hospital, the ethics committee of Beijing Red Cross Blood Center. Written informed consent was obtained for each patient.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 17, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
2-mercaptoethanol (2-ME)-based IATs or polybrene method mitigates the interference of anti-CD38 immunotherapy on blood compatibility tests
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
2-mercaptoethanol (2-ME)-based IATs or polybrene method mitigates the interference of anti-CD38 immunotherapy on blood compatibility tests
Ye Zhou, Leiyu Chen, Tianshu Jiang, Liangfeng Fan, Hang Lei, Yuqing Wang, Hasiyati Heililahong, Jianqing Mi, Danxin Du, Tianhong Miao, Rong Xia, Xuefeng Wang, Dong Xiang, Xiaohong Cai, Xiaofeng Tang
medRxiv 2020.12.14.20238311; doi: https://doi.org/10.1101/2020.12.14.20238311
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
2-mercaptoethanol (2-ME)-based IATs or polybrene method mitigates the interference of anti-CD38 immunotherapy on blood compatibility tests
Ye Zhou, Leiyu Chen, Tianshu Jiang, Liangfeng Fan, Hang Lei, Yuqing Wang, Hasiyati Heililahong, Jianqing Mi, Danxin Du, Tianhong Miao, Rong Xia, Xuefeng Wang, Dong Xiang, Xiaohong Cai, Xiaofeng Tang
medRxiv 2020.12.14.20238311; doi: https://doi.org/10.1101/2020.12.14.20238311

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Hematology
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (413)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (248)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (393)
  • Epidemiology (8550)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1744)
  • Geriatric Medicine (167)
  • Health Economics (371)
  • Health Informatics (1237)
  • Health Policy (619)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10281)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1670)
  • Nursing (97)
  • Nutrition (248)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (926)
  • Ophthalmology (263)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (112)
  • Palliative Medicine (40)
  • Pathology (252)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (247)
  • Primary Care Research (207)
  • Psychiatry and Clinical Psychology (1764)
  • Public and Global Health (3832)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (319)
  • Respiratory Medicine (520)
  • Rheumatology (207)
  • Sexual and Reproductive Health (165)
  • Sports Medicine (157)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (74)